---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-016168"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2025-09-30T23:59:59+00:00"
generated_at: "2026-05-17T05:18:38.110619+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MIRA completes SKNY acquisition, adds three pipeline programs; regains Nasdaq compliance

## Summary
- Acquired 100% of SKNY for restricted MIRA shares; SKNY contributed $5M in marketable securities to MIRA.
- Pipeline now includes Ketamir-2 (Phase 1 neuropathic pain), MIRA-55 (oral THC analog), and SKNY-1 (obesity/smoking cessation).
- Nasdaq had notified MIRA of stockholders' equity deficiency in April 2025; extension granted to Oct 6, 2025.
- After merger closing and ATM sales, MIRA believes it has regained compliance; Nasdaq will continue to monitor.
- No specific exchange ratio or deal value disclosed; valuations were independent third-party.

## SEC filing metadata
- accession: 0001493152-25-016168
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2025-09-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315225016168/0001493152-25-016168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315225016168/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-016168
- JSON: https://secwatch.observer/filing/0001493152-25-016168.json
- Plain text: https://secwatch.observer/filing/0001493152-25-016168.txt

## Key facts
- M&A Transactions
  MIRA PHARMACEUTICALS, INC. completed an acquisition involving SKNY Pharmaceuticals, Inc. for restricted shares of the Company’s common stock (closed 2025-09-29).
  - Action: acquisition
  - Counterparty: SKNY Pharmaceuticals, Inc.
  - Consideration: restricted shares of the Company’s common stock
  - Closing: 2025-09-29
  source text: On September 29, 2025, MIRA Pharmaceuticals, Inc. (the “Company”) completed its acquisition of SKNY Pharmaceuticals, Inc. (“SKNY”) pursuant to the previously announced merger agreement (the “Merger Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1904286/000149315225016168/0001493152-25-016168-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.